10 completed, 4 recruiting, 1 active not recruiting, 1 not yet recruiting. 16 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 10, Recruiting 4, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 3 | Completed 3 |
Follow Adult: new trials by email Literature Review of Adult trials Research Report on Adult
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis Intravenous fosmanogepix - End Stage Renal Disease on Dialysis, Adult | Phase 1 | Recruiting | Basilea Pharmaceutica | 20 | 2026-10-27 | 2026-11-04 |
| PIN in Combination With Sintilimab in Previously Treated pMMR/MSS CRC With Hepatic Metastases PIN+sintilimab - Colorectal Cancer, Adult | Phase 1 | Not yet recruiting | Chinese PLA General Hospital | 25 | 2026-03-01 | 2026-02-17 |
| PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma PIN +anti-PD1 - Hepatocellular Carcinoma, Adult | Phase 1 | Recruiting | Chinese PLA General Hospital | 25 | 2025-06-20 | 2025-06-22 |
| PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor PIN +anti-PD1 - Solid Tumor, Adult | Phase 1 | Recruiting | Chinese PLA General Hospital | 25 | 2025-03-19 | 2025-06-10 |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies KQB198, Dasatinib - Hematologic Malignancies, Adult | Phase 1 | Active not recruiting | Kumquat Biosciences Inc. | 13 | 2024-12-09 | 2026-03-25 |
| IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma IB-T101 injection - Advanced Clear Renal Cell Carcinoma, Adult | Phase 1 | Recruiting | Grit Biotechnology | 12 | 2024-12-06 | 2026-04-14 |
| A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants Ritlecitinib - Healthy Volunteers, Adult | Phase 1 | Completed | Pfizer | 12 | 2023-05-09 | 2024-10-16 |
| Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy Participants Lorlatinib 50 mg, Lorlatinib 75 mg, Lorlatinib 100 mg - Adult, Drug Interactions | Phase 1 | Completed | Pfizer | 16 | 2019-08-22 | 2020-01-18 |
| Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS - SYSTEMIC SCLERODERMA, ALLOGENEIC MESENCHYMAL STEM CELLS | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 20 | 2014-05-06 | 2024-05-01 |
| Effects of Rapid-Resisted Exercise and Bright Light Therapy on Ambulatory Adults With Traumatic Brain Injury Elliptical exercise - Adult, Traumatic Brain Injury | Phase 1 / Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 34 | 2011-08-24 | 2026-10-16 |
| Study Evaluating Single Ascending Doses of MR1817 MR1817, Placebo - Adult | Phase 1 | Completed | Mochida Pharmaceutical Company, Ltd. | 64 | 2010-07-01 | 2014-01-13 |
| Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040) Ertugliflozin 2 mg single dose, Ertugliflozin 2 mg split into twice daily, Ertugliflozin 4 mg single dose - Diabetes Mellitus, Type 2, Adult | Phase 1 | Completed | Merck Sharp & Dohme LLC | 52 | 2010-02-17 | 2019-11-21 |
| Development and Evaluation of a Nursing Virtual Intervention Tailored for Pain After Cardiac Surgery soulageTAVIE - Cardiac Surgery, Pain | Phase 1 / Phase 2 | Completed | Centre hospitalier de l'Université de Montréal (CHUM) | 60 | 2010-02-01 | 2010-09-15 |
| Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects SAM-531, placebo, Donepezil - Healthy, Adult | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 25 | 2007-10-01 | 2008-04-22 |
| Dose Ranging Study in Healthy Methadone Maintenance Subjects MOA-728 - Adult | Phase 1 | Completed | Bausch Health Americas, Inc. | 16 | 2006-06-01 | 2019-11-25 |
| LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors capecitabine, enzastaurin hydrochloride - Adult, Solid Tumor | Phase 1 | Completed | Jonsson Comprehensive Cancer Center | 16 | 2002-12-01 | 2020-08-03 |
Agnosia (1) · Alzheimer Disease (1) · Brain Injuries, Traumatic (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Diabetes Mellitus, Type 2 (1) · Hematologic Neoplasms (1) · Pain (1) · Pain, Postoperative (1) · Scleroderma, Systemic (1) · Stress Disorders, Post-Traumatic (1)
Neoplasms (3) · Neoplasms by Site (3) · Nervous System Diseases (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Mental Disorders (2) · Adenocarcinoma (1) · Brain Injuries (1) · Carcinoma (1) · Colonic Diseases (1) · Connective Tissue Diseases (1) · Craniocerebral Trauma (1) · Dementia (1)
Capecitabine (1) · Dasatinib (1) · Donepezil (1) · PF-06651600 (1) · SAM-531 (1) · ertugliflozin (1) · lorlatinib (1)
Chinese PLA General Hospital (3) · Pfizer (2) · Assistance Publique - Hôpitaux de Paris (1) · Basilea Pharmaceutica (1) · Bausch Health Americas, Inc. (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Grit Biotechnology (1) · Jonsson Comprehensive Cancer Center (1) · Kumquat Biosciences Inc. (1) · Merck Sharp & Dohme LLC (1) · Mochida Pharmaceutical Company, Ltd. (1) · National Institutes of Health Clinical Center (CC) (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1)
United States (5) · China (4) · France (3) · Belgium (2) · United Kingdom (2) · Canada (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1)
Lilin Ye, Ph.D (3) · Weidong Han, Ph.D (3) · Guanghua Rong, Ph.D (2) · Zhijun Wang, M.D (2) · Carolyn Britten, MD (1) · Jeff Cohn (1) · Robert Miller (1) · Silvina G Horovitz, Ph.D. (1) · Thomas Kaindl, MD (1)
PMID 23241361, PMID 30802200, PMID 33937953, PMID 34213819, PMID 34623637, PMID 36928395
2019 (1)